

Role of NGOs in the Cancer Mission

David Ritchie
Cancer Prevention Manager
Association of European Cancer Leagues (ECL)

“Conquering cancer – mission possible: coordination of actions in Baltic States”

16 December 2021



Co-funded by
the Health Programme
of the European Union

DECLARATIONS

ECL

- ⚡ ECL is independent of any political party or commercial interest.**
- ⚡ ECL's income is primarily through membership contributions, EU-funded projects and joint actions.**
- ⚡ ECL currently receives an Operating Grant from the European Commission under the Third EU Health Programme 2014-2021:**

FPA 2017 (785273)




Co-funded by
the Health Programme
of the European Union

- ⚡ ECL has an unrestricted education grant with L'Oréal Garnier International.**



-



ROLE OF NGOs

Addressing the gaps




Supporting sustainability



Proximity to citizens



13 Citizen- and patient-centred recommendations for actions of the Mission on Cancer



Objective: To assess the effectiveness and feasibility of personalised breast cancer screening, one that is based on the personal risk of developing breast cancer for each individual woman

Overview: To meet this objective, a multi-centre, international, randomised clinical study will take place, recruiting 85,000 women from Belgium, France, Israel, Italy, the United Kingdom and Spain. This study will compare the current standard breast screening with a personalised strategy, which screens women at higher risk of breast cancer more often, and women at a lower risk of breast cancer less often.


Partners: A consortium of 26 partners from 7 different countries, coordinated by Unicancer, including many leading doctors, scientists and researchers, as well as patient representatives and advocates (incl. ECL)

Duration: 8 years (2018-2025)

Funding: €12.5 million euros from the Horizon 2020 research and innovation programme (H2020-EU.3.1.3. - Treating and managing disease)


<https://www.mypebs.eu/>

Study design




Belgium France Israel Italy Netherlands United States United Kingdom

MEMBERS OF THE MYPEBS CONSORTIUM



ASSOCIATED PARTNERS







MyPeBS' expected outcomes

Planned outcomes



Strong evidence to sustain (or not) the implementation of **risk-based screening in the general population**
(future EU recommendations)

Efficacy and risk/benefits

Target populations

Cost

Psycho-social impact

Tools ready for implementation

Preparation of stakeholders

Potential additional outcomes



From images and biobank:

New risk models and softwares

New cancer risk genes and SNPs

New Prevention biomarkers



Substudies

Imaging

Prevention


Early detection



New economical models



MyPeBS: 27 consortium partners



UNICANCER – trial sponsor and project coordinator
Gustave Roussy – stats & study PI France
Statlife – risk calculation, imaging (breast density)
CNGE (GPs association) - material for investigators training
Paris 13 University– ethics and psycho-sociology
University Lyon1 - psycho-socio
ARC Foundation – communication & dissemination
Santé Publique France – access to social security data
CNRGH/CEA – Genotyping
CEPH-Fondation Jean Dausset – DNA extraction from saliva
Associated partners: NCI (INCa), screening structures, patients associations, gynecologists, radiologists



Assuta Medical Centers : study PI Israel and investigation
Maccabi Healthcare Services: investigation



ERASMUS University – medico-economics



Catalonia

Hospital del Mar Barcelona– study PI, investigation and psycho socio



Univ California San Francisco – WISDOM « sister » study



University of Cambridge – study PI and genetics
University of Manchester - investigation + psycho-socio + risk calculation (TC)
University of Nottingham – radiology QC
Queen Mary University of London - Recommendations
ICPV (independant cancer patients' voice)- patients advocacy



Azienda Unità Sanitaria Locale Reggio Emilia-(AUSL-RE) – study PI Italy and tomosynthesis
- investigation + communication
Istituto Scientifico Azienda Ospedaliera Città della Salute e della Scienza di Torino (CPO-AOU) Romagnolo per lo Studio e la Cura dei Tumori (IRST-IRCCS) - investigation
Institute for Study and Cancer Prevention (ISPO)- investigation
Im3D- imaging (breast density)
Associated partners: Screening centres from Este-monselice and Lombardy regions

WP6: general communication (general public, stakeholders) + dissemination of results/findings




Institut Jules Bordet : Study PI Belgium, investigation
European Cancer League : communication
EONIX: webplatform development
Intuitim: trusted third party – data host
Associated partners: Screening centres from Flandres, Wallonie and Brussels regions; Fondation contre le Cancer



CBIG-SCREEN


Project | A collaborative approach
to cervical cancer screening



Steps of the CBIG-SCREEN project, shown as a health policy cycle.
We will build capacity for RBCCS implementation and monitoring throughout the project

> THE CONCEPT

Three major pillars support the concept of CBIG-SCREEN



Co-creating the offer of cervical screening with vulnerable groups for vulnerable groups

5

Years
2021-2026

14

Partners
in the project

10

European
countries

€3.6

Million funding
from Horizon
2020

CONTACT

- **Scientific Coordinator:**
Marc Bardou, Inserm
[E-mail](#)
- **Project Manager:**
Christiane Dascher-Nadel, Inserm-Transfert
[E-mail](#)

marc.bardou@u-bourgogne.fr

christiane.dascher-nadel@inserm-transfert.fr

THE CONSORTIUM




France Denmark United Kingdom Italy Portugal Estonia Romania
Ireland Bulgaria Belgium



Tartu Ülikool (UTARTU)

Anneli Uusküla



CBIG-SCREEN, a 5-year collaborative research project, has received funding from the EU Horizon 2020 Research and Innovation Programme under Grant Agreement No 964049. Official starting date: 01. March 2021

© 2006 The Authors



ECL Association of European Cancer Leagues

